Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

ted a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

In a 4-week Phase 1 combination study that was conducted in 50 treatment-naive patients chronically infected with HCV genotype 1, R7128 demonstrated potent short-term antiviral activity and was generally safe and well tolerated. Eighty-five percent (85%) of patients receiving R7128 1500mg twice-daily (BID) with Pegasys plus Copegus for 4 weeks achieved undetectable HCV RNA levels with safety and tolerability comparable to placebo with Pegasys plus Copegus.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Ra
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , Puerto Rico , May 17, ... central and western Puerto Rico , Caribbean ... PR) Center has improved its radiation therapy capabilities with the ... Puerto Rico . Versa HD offers clinicians ... range of tumors throughout the body, while also enabling treatment ...
(Date:5/17/2013)... , May 17, 2013  PENTAX Medical, a ... Medical, a global leader in ultrasound imaging, recently ... companies to enable further innovation in the development ... Hitachi-Aloka ultrasound systems and PENTAX Medical endoscopic portfolio ... families of EUS systems. This agreement will continue ...
(Date:5/17/2013)... May 17, 2013 Oramed Pharmaceuticals ... oral drug delivery systems, announced today that the United ... Company,s Investigational New Drug application(IND) for ORMD-0801, its oral ... have the FDA clearance to proceed," stated ... trial is a major milestone for Oramed and we ...
Breaking Medicine Technology:Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... LUND, Sweden, July 3 ,ThromboGenics NV (Euronext Brussels: THR) ... have started,recruitment of a second cohort of patients for ... recruitment of the first cohort of 100,patients ahead of ... being developed for the prevention of deep vein thrombosis ...
... The largest study of,the genetics of schizophrenia ever undertaken ... the human genome (SNPs) linked to,risk of the disease. The ... from deCODE genetics (Nasdaq: DCGN ), analyzed the genomes ... is published today in the online edition of Nature. , ...
Cached Medicine Technology:ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 2ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 3ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 4ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402 5deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5
(Date:5/18/2013)... 2013 Dr. Robert Tracey, an area leader ... employs his knowledge of the root causes of sleep apnea ... May being Better Sleep Month, Dr. Tracey points out estimates ... sleep disorder, and sleep apnea is one of the most ... will essentially stop breathing at different times while sleeping. When ...
(Date:5/18/2013)... Wisconsin (PRWEB) May 18, 2013 Scott Tischler ... in 90 days. These five keys to losing weight played ... help and support of Scott Tischler, Troy was able to ... that any weight loss program should be approached with caution ... pain. These are the five keys to weight loss that ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 John Ravera, ... announced the addition of a new member to his dental ... has worked in the field for over 10 years. She ... with honors, and was elected a member of Sigma Pi ... hygiene profession. Marino enjoys working with patients of all ages, ...
(Date:5/18/2013)... 2013 Kimono condoms assorted sampler ... condom store recently announced. Condomania recently added new ... selection of condoms from all over the world. ... to try different condom styles from one of the ... classic comfortable shape and secure, the new packs contain ...
(Date:5/18/2013)... May 18, 2013 According to the the ... as Toxic Epidermal Necrolysis, is a severe allergic reaction usually ... flu-like symptoms but it can quickly advance causing blistering and ... even cause death. SJS can develop at any time ... the former NBA player, Manute Bol, passed away after he ...
Breaking Medicine News(10 mins):Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:Kimono Condoms Assorted Sampler Packs Now Available at Condomania 2Health News:Injury Law Firm Announces New Informative Graphic on Common Medicines That Have Allegedly Been Linked to Stevens Johnson Syndrome 2
... a state of serious impairments in both learning ability ... one of the most prevalent conditions in child psychiatry, ... adulthood. ADHD is conservatively estimated to occur in 3,07,5% ... permissive criteria yield estimates of up to 17% (Barbaresi ...
... Just one week after,Cover All Pennsylvanians, the ... the General Assembly, Governor Edward G.,Rendell today visited ... "Tour to,Insure." The five-day, nine-stop tour has highlighted ... coverage. The Lehigh Valley has nearly 37,000,uninsured adults., ...
... no difference in motorists, reaction times , , SATURDAY, Oct. ... pain medications such as morphine does not impair a ... at Rush University Medical Center in Chicago compared two ... morphine and 49 who weren,t taking any pain medication. ...
... Holdings, Inc. (Nasdaq: NHWK ), a leading provider ... today announced that,it will host a conference call on ... to review the company,s third quarter results. Conference ... call will be held on Wednesday, October,31, 2007 at ...
... Medical Injustice, Will Challenge,Corporate-Backed Proponents of "Health Courts", ... Dale Nance, co-author of the groundbreaking new report ... the featured speakers at a,patient safety forum in ... debate the merits and weaknesses of the health ...
... SAN DIEGO, Oct. 12 MediKeeper,( http://www.medikeeper.com ), ... and wellness industry, has closed its Series A ... MediKeeper was started in 2003 by a ... of making medical records secure, mobile,and accessible online. ...
Cached Medicine News:Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 2Health News:Computerized training of working memory is a promising therapeutic strategy in ADHD 3Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 2Health News:Governor Rendell's 'Tour to Insure' Urges Passage of Plan to Give Access to Affordable Health Insurance 3Health News:Morphine Painkillers Won't Impair Driving 2Health News:NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call 2Health News:'Health Courts' Critic to be Featured Speaker at Wyoming Patient Safety Panel 2Health News:MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: